主营业务收入增长稳健，优势领域创新管线持续推进

■ 京新药业 — 沪深300指数 | --- | --- | --- | --- | --- | --- | |---------------------|-------|-------|-------------------------|-------|-------| | | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业收入 ( 百万元 ) | 3,780 | 3,999 | 4,399 | 5,019 | 5,770 | | YOY(%) | 13.3 | 5.8 | 10.0 | 14.1 | 15.0 | | 净利润 ( 百万元 ) | 662 | 619 | 698 | 821 | 977 | | YOY(%) | 7.9 | -6.5 | 12.7 | 17.6 | 19.1 | | 毛利率 (%) | 53.3 | 50.6 | 53.1 | 55.7 | 57.5 | | 净利率 (%) | 17.5 | 15.5 | 15.9 | 16.4 | 16.9 | | ROE(%) | 12.9 | 11.2 | 11.6 | 12.4 | 13.3 ...